Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Latest Information Update: 13 May 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
- Indications Hodgkin's disease; Lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BAL
- 07 May 2024 Planned End Date changed from 1 Jun 2024 to 30 Nov 2024.
- 07 May 2024 Status changed from recruiting to suspended.
- 03 Oct 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.